Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

Health Care

General

Acelyrin Announced That Results From Its Global Phase 3 Trial Of Izokibep In Moderate-to-severe Hidradenitis Suppurativa Patients Will Be Shared At The 2024 European Academy Of Dermatology And Venereology - Acelyrin (NASDAQ:SLRN)

Benzinga Newsdesk

Acelyrin

SLRN

Acelyrin Announced That Results From Its Global Phase 3 Trial Of Izokibep In Moderate-to-severe Hidradenitis Suppurativa Patients Will Be Shared At The 2024 European Academy Of Dermatology And Venereology

Comments